Antengene Corporation Limited (HK:6996)
:6996
Want to see HK:6996 full AI Analyst Report?
6996 Stock Chart & Stats
HK$5.27
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$5.27
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$2.68 - HK$8.16
Previous CloseN/A
Volume1.25M
Average Volume (3M)1.88M
Market Cap
HK$2.29B
Enterprise ValueHK$1.87B
Total Cash (Recent Filing)HK$734.29M
Total Debt (Recent Filing)HK$257.51M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Aug 21, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding679,446,660
10 Day Avg. Volume1,689,397
30 Day Avg. Volume1,876,149
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.32
Price to Sales (P/S)20.24
P/FCF Ratio-11.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$9.60Price Target Upside82.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.37
Revenue Forecast (FY)HK$703.70M
Bulls Say, Bears Say
Bulls Say
Diversified Commercial And Licensing Revenue ModelA mix of product sales, licensing/collaboration milestones and service income creates multiple durable funding channels. This reduces binary reliance on a single approval, allows milestone-driven financing of R&D, and supports commercialization investment in Asia over the medium term.
Improving Revenue Growth With Positive Gross ProfitMaterial top-line acceleration and sustained positive gross margin indicate product-level economics are solid. As scale increases, these margins can enable operating leverage, fund further R&D and commercialization, and support durability of business operations over the coming months.
Low, Improving Leverage Gives Financial FlexibilityModest and declining leverage reduces refinancing and default risk, preserving capacity to raise capital or absorb trial setbacks. This balance-sheet flexibility is important for a clinical/commercial biotech funding ongoing trials and regional commercialization without immediate solvency pressure.
Bears Say
Persistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow means the business still depends on external capital or partner payments to fund operations. This erodes liquidity over time, increases dilution or refinancing needs, and constrains strategic optionality if capital markets tighten in the medium term.
Ongoing Deep Operating And Net LossesPersistent large operating and net losses reflect a structural mismatch between current revenues and required R&D/commercial spend. Until profitability approaches sustainably, the company will face pressure on reserves and depend on capital markets or deal flow to continue long-term development and commercialization plans.
Eroding Equity And Negative Return On EquityDeclining equity and a large negative ROE indicate capital erosion and value destruction. That reduces the balance-sheet buffer against clinical setbacks, raises stakeholder risk, and increases the likelihood of future dilution or costly financing if operating losses persist over the medium term.
Antengene Corporation Limited News
6996 FAQ
What was Antengene Corporation Limited’s price range in the past 12 months?
Antengene Corporation Limited lowest stock price was HK$2.68 and its highest was HK$8.16 in the past 12 months.
What is Antengene Corporation Limited’s market cap?
Antengene Corporation Limited’s market cap is HK$2.29B.
When is Antengene Corporation Limited’s upcoming earnings report date?
Antengene Corporation Limited’s upcoming earnings report date is Aug 21, 2026 which is in 77 days.
How were Antengene Corporation Limited’s earnings last quarter?
Antengene Corporation Limited released its earnings results on Mar 20, 2026. The company reported -HK$0.3 earnings per share for the quarter, the consensus estimate of -HK$0.3 by HK$0.
Is Antengene Corporation Limited overvalued?
According to Wall Street analysts Antengene Corporation Limited’s price is currently Undervalued.
Does Antengene Corporation Limited pay dividends?
Antengene Corporation Limited does not currently pay dividends.
What is Antengene Corporation Limited’s EPS estimate?
Antengene Corporation Limited’s EPS estimate is 0.41.
How many shares outstanding does Antengene Corporation Limited have?
Antengene Corporation Limited has 679,446,660 shares outstanding.
What happened to Antengene Corporation Limited’s price movement after its last earnings report?
Antengene Corporation Limited reported an EPS of -HK$0.3 in its last earnings report, expectations of -HK$0.3. Following the earnings report the stock price went up 0.247%.
Which hedge fund is a major shareholder of Antengene Corporation Limited?
Currently, no hedge funds are holding shares in HK:6996
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Antengene Corporation Limited
Antengene Corporation Limited (6996) is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for cancer treatment. The company operates primarily in the biopharmaceutical sector, concentrating on the development of monoclonal antibodies, small molecules, and other biologics aimed at addressing unmet medical needs in oncology. Antengene's core products include a pipeline of drug candidates designed to target various cancers, with efforts in both domestic and international markets.
6996 Stock 12 Month Forecast
Average Price Target
HK$9.60
▲(82.16% Upside)
Technical Analysis
Innovent Biologics
―
Alphamab Oncology
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---